Crystal habit of quinoline derivative and preparation method for crystalline powder thereof
The present application relates to the field of pharmaceutical technology, specifically to the crystal habit and crystalline powder preparation of quinoline derivatives, and more specifically, to the crystal habit and crystalline powder preparation of anlotinib dihydrochloride. The compound of formula II disclosed herein is a crystalline powder with a flaky crystal habit having a specific surface area ≥10 m 2 /g and a particle-size distribution of X 50 ≤50 μm and/or X 90 ≤500 μm, such that a large specific surface area is provided without reducing the particle size of the drug by a physical method under the condition of a broad particle-size distribution, and the drug can rapidly dissolving. In addition to excellent dissolution property, the crystalline powder is also beneficial to industrial manufacturing, featuring simplified process and cost-efficiency.
1. A crystalline powder of the compound of formula II, comprising crystals exhibiting a thin flaky or an aggregated flaky habit, the crystalline powder comprising a specific surface area ≥10 m 2 /g and a particle-size distribution of X 50 ≤50 μm and/or X 90 ≤500 μm,
wherein, in an X-ray diffraction (XRD) pattern using Cu-Kα radiation, the crystals have diffraction peaks at the following 2θ of 7.83±0.2°, 8.83±0.2°, 10.29±0.2°, 14.63±0.2°, 24.60±0.2° and 27.37±0.2°.
2. The crystalline powder according to claim 1 , wherein the crystalline powder comprises a specific surface area of 10 to 50 m 2 /g.
3. The crystalline powder according to claim 2 , wherein the crystalline powder comprises a specific surface area of 10 to 25 m 2 /g.
4. The crystalline powder according to claim 2 , wherein the crystalline powder comprises a specific surface area of 10 to 15 m 2 /g.
5. The crystalline powder according to claim 1 , wherein the particle-size distribution of the crystalline powder is 20 μm≤X 50 ≤50 μm and/or 300 μm≤X 90 ≤500 μm.
6. The crystalline powder according to claim 1 , prepared by a method comprising:
(1) slurrying the compound of formula II with one or more organic solvents selected from ethanol, ethyl acetate, methanol, and acetone by stirring, mixing and separating until no liquid flows out, thereby preparing a mixture;
(2) heating and drying the mixture under reduced pressure; and
(3) optionally, pulverizing and mixing,
thereby preparing the crystalline powder.
7. The crystalline powder according to claim 1 , wherein, in the X-ray diffraction (XRD) pattern using Cu-Kα radiation, the crystals additionally have diffraction peaks at the following 2Θ 9.56±0.2°, 13.90±0.2°, 19.40±0.2°, 20.19±0.2°, 22.35±0.2° and 22.91±0.2°.
8. The crystalline powder according to claim 1 , wherein, in the X-ray diffraction (XRD) pattern using Cu-Kα radiation, the crystals additionally have diffraction peaks at the following 2Θ 9.56±0.2°, 13.90±0.2°, 15.34±0.2°, 15.93±0.2°, 17.32±0.2°, 18.70±0.2°, 19.40±0.2°, 20.19±0.2°, 22.35±0.2°, 22.91±0.2°, 25.64±0.2°, 28.17±0.2° and 29.94±0.2°.
9. The crystalline powder according to claim 1 , wherein, in the X-ray diffraction (XRD) pattern using Cu-Kα radiation, the crystals have an XRD pattern essentially identical to FIG. 1 .
10. The crystalline powder according to claim 1 , wherein the particle-size distribution of the crystalline powder is X 50 ≤20 μm and/or 150 μm≤X 90 ≤300 μm.
11. The crystalline powder according to claim 1 , wherein the particle-size distribution of the crystalline powder is X 50 ≤10 μm and/or 70 μm≤X 90 ≤150 μm.
12. A crystalline powder composition, comprising the crystalline powder according to claim 1 in an amount that accounts for 70 wt % or more by weight of the crystalline powder composition.
13. A crystalline powder composition, comprising the crystalline powder according to claim 1 in an amount that accounts for 50 wt % or more by weight of the crystalline powder composition.
14. A pharmaceutical composition, comprising the crystalline powder composition according to claim 13 , and one or more pharmaceutically acceptable carriers.
15. A pharmaceutical composition, comprising the crystalline powder according to claim 1 , and one or more pharmaceutically acceptable carriers.
16. A method for treating non-small cell lung cancer, comprising administering to a patient in need thereof a therapeutically effective amount of the pharmaceutical composition according to claim 15 .
17. A method for preparing the crystalline powder according to claim 1 , the method comprising:
(1) slurrying the compound of formula II with one or more organic solvents selected from ethanol, ethyl acetate, methanol, and acetone by stirring, mixing and separating until no liquid flows out thereby preparing a mixture;
(2) heating and drying the mixture under reduced pressure; and
(3) optionally, pulverizing and mixing,
thereby preparing the crystalline powder.
18. The method for preparation according to claim 17 , wherein the one or more organic solvents are selected from ethanol, ethyl acetate, and a mixture of ethanol and ethyl acetate.